Safety and Immunogenicity of V540B in Healthy Adults (V540B-002).

Condition(s) studied

Investigational drug(s) / intervention(s)

GARDASIL®9 (G9): Suspension administered via intramuscular (IM) injection

V540B: Experimental vaccine and adjuvant administered via IM injection

Study summary

Researchers are looking for new ways to prevent cancers related to human papillomavirus (HPV). HPV is a common virus that can cause an infection. There are many different types of HPV. Most people's immune system can fight HPV infection and it goes away without treatment. For some people, HPV infections can last longer and may cause cancer years later.

A standard vaccine to prevent HPV-related cancers is GARDASIL®9 (G9). G9 protects against 9 types of HPV but it does not protect against other types of HPV. The study vaccine (called V540B) is designed to protect against the same HPV types that G9 protects against plus other HPV types. The main goal of this study is to learn about the safety of V540B in healthy adults and if people tolerate it.

Eligibility

Primary outcome measure(s)

• Number of Participants Who Experience a Solicited Injection-Site Adverse Event (AE) — Up to approximately 6 months
  An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
• Number of Participants Who Experience a Solicited Systemic AE — Up to approximately 6 months
  Solicited systemic AEs include headache, fatigue, nausea, dizziness, muscle aches, joint pain.
• Immediate Reactions Occurring Within 30 Minutes After Any Vaccination — Up to approximately 6 months
  An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
• Number of Participants Who Experienced Unsolicited AEs — Up to approximately 7 months
  An unsolicited AE is an AE that was not solicited using a vaccine report card (VRC) and that is communicated by a participant (or their legally acceptable representative, if applicable). Unsolicited AEs include serious and nonserious AEs.
• Number of Participants Who Experienced a Serious Adverse Event — Up to approximately 18 months
  Serious adverse events (SAEs) include adverse events that result in any of the following outcomes: death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal functions, or a congenital anomaly/birth defect.
• Number of Participants Who Experienced a Medically-Attended AE — Up to approximately 18 months
  AEs in which medical attention is received during an unscheduled, non-routine outpatient visit, such as an emergency department visit, office visit, or an urgent care visit with any medical personnel for any reason. Routine visits are not considered medically-attended adverse events (MAAEs). Examples of routine visits include physical examination, wellness visits, or vaccinations.
• Number of Participants Who Experienced an Event of Clinical Interest — Up to approximately 18 months
  Events of clinical interest (ECIs) are defined as an overdose of Sponsor's product, drug-induced liver injury events, or potential immune-mediated diseases (pIMDs).

Trial sites (5)

More Merck Sharp & Dohme LLC trials in the USA

Other trials for the same condition